What's Happening?
Trisk Bio Ltd, a UK-based contract development and manufacturing organization (CDMO) specializing in adeno-associated virus (AAV) production, has partnered with NanoMosaic, Inc., a leader in advanced analytical technologies for cell and gene therapy.
This collaboration aims to integrate NanoMosaic's Tessie analytics platform into Trisk Bio's AAV process development, quality control, and release testing workflows. The Tessie platform is recognized for its high sensitivity and specificity in analyzing proteins and nucleic acids, providing novel Critical Quality Attributes (CQAs) essential for cell and gene therapy development. Trisk Bio's early adoption of the Tessie platform aligns with the FDA's Advanced Manufacturing Technology (AMT) designation, which assures developers that their analytical methods meet regulatory expectations. This partnership is expected to enhance the accuracy of AAV analytics, reducing the risk of misreading critical quality attributes.
Why It's Important?
The partnership between Trisk Bio and NanoMosaic is significant for the gene therapy industry, particularly in the U.S., as it promises to improve the reliability and accuracy of AAV analytics. This advancement is crucial for ensuring the quality and safety of gene therapies, which are increasingly being developed to treat a variety of genetic disorders. By embedding the Tessie platform, Trisk Bio can offer its clients more precise measurements, potentially accelerating the development and approval of new therapies. This collaboration also highlights the growing importance of advanced analytical technologies in meeting regulatory standards, which can facilitate smoother transitions from development to clinical trials. As the demand for gene therapies continues to rise, innovations like these are essential for maintaining high standards in manufacturing and quality control.
What's Next?
Representatives from Trisk Bio and NanoMosaic will discuss their partnership at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, scheduled for May 11-15, 2026. This event will provide an opportunity for industry stakeholders to learn more about the benefits of the Tessie platform and its impact on AAV analytics. As the partnership progresses, it is likely that other CDMOs and biotech companies will take interest in similar technologies to enhance their own processes. The success of this collaboration could lead to broader adoption of advanced analytics in the gene therapy sector, potentially influencing regulatory practices and industry standards.
